Shenzhen Hepalink Pharmaceutical, the Shenzhen-listed Heparin producer, has injected $60 million into TPG Biotechnology Partners V with purposes to improve the fund’s efficiency and explore new business opportunities, according to the Chinese firm’s statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
